Q1 Earnings Forecast for Longeveron Issued By HC Wainwright

Longeveron Inc. (NASDAQ:LGVN) – Investment analysts at HC Wainwright upped their Q1 2025 EPS estimates for shares of Longeveron in a note issued to investors on Monday, March 3rd. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings of ($0.37) per share for the quarter, up from their previous estimate of ($0.40). HC Wainwright has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for Longeveron’s current full-year earnings is ($3.69) per share. HC Wainwright also issued estimates for Longeveron’s Q2 2025 earnings at ($0.35) EPS, Q3 2025 earnings at ($0.31) EPS, Q4 2025 earnings at ($0.31) EPS and FY2025 earnings at ($1.31) EPS.

LGVN has been the topic of several other reports. Roth Capital upgraded shares of Longeveron to a “strong-buy” rating in a research report on Thursday, December 5th. Roth Mkm began coverage on shares of Longeveron in a research report on Friday, December 6th. They set a “buy” rating and a $10.00 price objective on the stock.

Longeveron Stock Performance

NASDAQ LGVN opened at $1.44 on Thursday. Longeveron has a twelve month low of $0.77 and a twelve month high of $6.40. The stock has a market cap of $21.37 million, a price-to-earnings ratio of -0.23 and a beta of 0.37. The firm’s 50 day moving average price is $1.64 and its two-hundred day moving average price is $1.89.

Hedge Funds Weigh In On Longeveron

Several institutional investors and hedge funds have recently modified their holdings of the stock. Jane Street Group LLC purchased a new position in shares of Longeveron during the 4th quarter valued at $35,000. Northern Trust Corp purchased a new position in shares of Longeveron during the 4th quarter valued at $31,000. Virtu Financial LLC purchased a new position in shares of Longeveron during the 4th quarter valued at $53,000. Geode Capital Management LLC grew its holdings in shares of Longeveron by 316.0% during the 3rd quarter. Geode Capital Management LLC now owns 128,947 shares of the company’s stock valued at $250,000 after acquiring an additional 97,953 shares in the last quarter. Finally, State Street Corp purchased a new position in shares of Longeveron during the 3rd quarter valued at $29,000. 10.01% of the stock is currently owned by hedge funds and other institutional investors.

About Longeveron

Longeveron Inc, a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company’s lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors.